Cell Reports (Mar 2016)

The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals

  • A. Alicia Koblansky,
  • Agnieszka D. Truax,
  • Rongrong Liu,
  • Stephanie A. Montgomery,
  • Shengli Ding,
  • Justin E. Wilson,
  • W. June Brickey,
  • Marcus Mühlbauer,
  • Rita-Marie T. McFadden,
  • Peizhen Hu,
  • Zengshan Li,
  • Christian Jobin,
  • Pauline Kay Lund,
  • Jenny P.-Y. Ting

DOI
https://doi.org/10.1016/j.celrep.2016.02.064
Journal volume & issue
Vol. 14, no. 11
pp. 2562 – 2575

Abstract

Read online

NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1−/− mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1−/−Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.